Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0025 + Chemotherapy in Advanced or Recurrent Endometrial Cancer
NCT07902999Phase 3Recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 3 trial of sotiburafusp alfa in endometrial cancer (EC), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Started Oct 2026; status: recruiting.
02
Drugs
sotiburafusp alfa
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07902999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902999.